Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

NCT03425539 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Lucerastat
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.